Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma

This trial tests whether using talquetamab (a bispecific antibody targeting myeloma cells) combined with lenalidomide as maintenance therapy after a stem cell transplant can keep multiple myeloma in deep remission for longer. **You may be eligible if...** - You have been diagnosed with multiple myeloma and confirmed by standard diagnostic criteria - Your myeloma showed measurable disease at the time of original diagnosis - You have completed induction therapy and had a stem cell transplant, and are in remission - You are not currently relapsed or refractory **You may NOT be eligible if...** - You cannot tolerate lenalidomide at even a low dose (10 mg or 5 mg) - Your myeloma has relapsed or been refractory at any point before enrollment - You have previously received GPRC5D-directed therapy or T-cell redirection therapy (e.g., bispecific antibodies or CAR-T targeting myeloma) - You have serious allergies to the study drugs Talk to your doctor to see if this trial is right for you.